Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 31 | SFEBES2013 | Next issue

Society for Endocrinology BES 2013

Clinical Management Workshops

Management controversies in parathyroid disease

Table of contents
Next section
How Do I Do It?

ea0031cmw1.1 | Management controversies in parathyroid disease | SFEBES2013

Abstract unavailable....
0 shares

ea0031cmw1.2 | Management controversies in parathyroid disease | SFEBES2013

Abstract unavailable....
0 shares

ea0031cmw1.3 | Management controversies in parathyroid disease | SFEBES2013

Abstract unavailable....
0 shares

ea0031cmw1.4 | Management controversies in parathyroid disease | SFEBES2013

Medical management of primary hyperparathyroidism

Hosking David

Surgical parathyroidectomy remains the most cost effective treatment for primary hyperparathyroidism but where surgery is inappropriate because of significant co-morbidity there is a place for medical therapy. Calcimimetics are type II agonists (requiring calcium for activity) of the calcium sensing receptor (CaSR). The first compound of this class is cinacalcet which reduces PTH by about 50% at 4 h with recovery to within 20% of baseline over the next 8 h. Despite these fluct...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more